title: In vitro interaction between two antineoplastic drugs--phopurinum and interferon alpha 2.
abstract: Induction of sister chromatid exchanges (SCEs) and chromosome aberrations (CAs) by two antineoplastic drugs--phopurinum (2-dimethylamino-6-diethyleneiminophosphamido-7-methylpurine) and recombinant human interferon alpha 2 (rHuIFN-alpha 2) was studied in human lymphocytes in vitro. Phopurinum was found to cause a significant increase of both SCEs and CAs in lymphocytes, while rHuIFN-alpha 2 induced only SCEs. Combined treatment with these two drugs reduced SCE and CA levels as compared with those induced by phopurinum alone. The maximal extent of reduction, however, was observed at intermediate doses of phopurinum.
authors.affiliation: Ecological Genetics Laboratory, Vilnius University, Lithuanian S.S.R.
authors.forename: J R
authors.initials: JR
authors.lastname: Lazutka
authors.forename: G
authors.initials: G
authors.lastname: Slapsyte
authors.forename: S
authors.initials: S
authors.lastname: Jarmalaite
authors.forename: R K
authors.initials: RK
authors.lastname: Lekevicius
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000633:toxicity*; D001388:Aziridines; D002869:Chromosome Aberrations; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology* / Q000633:toxicity; D009943:Organophosphorus Compounds / Q000633:toxicity*; D011687:Purines / Q000633:toxicity*; D011994:Recombinant Proteins; D012854:Sister Chromatid Exchange / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D001388:Aziridines; D007370:Interferon Type I; D009943:Organophosphorus Compounds; D011687:Purines; D011994:Recombinant Proteins; C015893:pumitepa